Anti-PAI1 Antikörper (A283160)

Anti-PAI1 Antibody - BSA and Azide free

Rabbit polyclonal antibody to PAI1.

This antibody recognises human PAI-1, also known as plasminogen activator inhibitor-1 or SERPINE1. PAI-1 is a ~45 kDa serine protease inhibitor and member of the serpin family, which acts as the primary inhibitor of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), and hence fibrinolysis.Mutations of the SERPINE1 gene are associated with Plasminogen activator inhibitor-1 deficiency (PAI-1D), a condition characterized by episodes of severe hemorrhage. Heterozygous carriers of the mutation do not display the same phenotype, instead demonstrate longer teleomere length, lower incidence of diabetes and increased longevity. Increased levels of PAI-1 are associated with diabetes, cardiovascular disease and an increased occurrence of thrombosis in obesity, and can be induced by obesity related factors including insulin, glucose and very-low-density lipoprotein.

WB, ELISA, IHC-P

ELISA: 0.5 - 2 µg/ml, WB: 0.1 - 0.2 µg/ml

Human

Recombinant human PAI-1.

Rabbit

Polyclonal

IgG

Unconjugated

1 mg/ml after reconstitution.

Reconstitute with 0.1 ml of distilled water. For long term storage the addition of 0.09% sodium azide is recommended.

Supplied in Phosphate Buffered Saline.

Lyophilized: Store at -20°C. Reconstituted: Store undiluted at -20°C, avoid freeze / thaw cycles. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.

Rabbit anti Human PAI-1 antibody recognises human PAI-1, also known as plasminogen activator inhibitor-1 or SERPINE1. PAI-1 is a ~45 kDa serine protease inhibitor and member of the serpin family, which acts as the primary inhibitor of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), and hence fibrinolysis.Mutations of the SERPINE1 gene are associated with Plasminogen activator inhibitor-1 deficiency (PAI-1D), a condition characterized by episodes of severe hemorrhage (Saes et al. 2019). Heterozygous carriers of the mutation do not display the same phenotype, instead demonstrate longer teleomere length, lower incidence of diabetes and increased longevity (Khan et al. 2017).Increased levels of PAI-1 are associated with diabetes, cardiovascular disease and an increased occurrence of thrombosis in obesity, and can be induced by obesity related factors including insulin, glucose and very-low-density lipoprotein (Altalhi et al. 2021).

Clade E, Endothelial plasminogen activator inhibitor, Nexin, PAI, PAI 1, PAI-1, PAI1_HUMAN, PLANH1, Plasminogen activator inhibitor 1, Plasminogen activator inhibitor type 1, Serine (or cysteine) proteinase inhibitor, Serine (or cysteine) proteinase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1, Serpin E1, Serpin peptidase inhibitor clade E, Serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1, Serpine 1, SERPINE1